Suberoylanilide Hydroxamic Acid (Vorinostat) Up-regulates Progranulin Transcription
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Progranulin (GRN) haploinsufficiency is a frequent cause of familial frontotemporal dementia, a currently untreatable progressive neurodegenerative disease. By chemical library screening, we identified suberoylanilide hydroxamic acid (SAHA), a Food and Drug Administration-approved histone deacetylase inhibitor, as an enhancer of GRN expression. SAHA dose-dependently increased GRN mRNA and protein levels in cultured cells and restored near-normal GRN expression in haploinsufficient cells from human subjects. Although elevation of secreted progranulin levels through a post-transcriptional mechanism has recently been reported, this is, to the best of our knowledge, the first report of a small molecule enhancer of progranulin transcription. SAHA has demonstrated therapeutic potential in other neurodegenerative diseases and thus holds promise as a first generation drug for the prevention and treatment of frontotemporal dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
Araki, T., Sasaki, Y., & Milbrandt, J. (2004) · Science · doi:10.1126/science.1098014 · Cited by 1,060
SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1
Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R. S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088682 · Cited by 915
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice
Yin, F., Banerjee, R., Thomas, B., Zhou, P., Qian, L., Jia, T., Ma, X., Ma, Y., Iadecola, C., Beal, M. F., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091568 · Cited by 480
Cited by
Bang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Self-citationEpigenetic mechanisms in neurological disease
Jakovcevski, M., & Akbarian, S. (2012) · Nature Medicine · doi:10.1038/nm.2828 · Cited by 450
Advances in understanding the molecular basis of frontotemporal dementia
Rademakers, R., Neumann, M., & Mackenzie, I. R. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.117 · Cited by 412
Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury
Martens, L. H., Zhang, J., Barmada, S. J., Zhou, P., Kamiya, S., Sun, B., Min, S.-W., Gan, L., Finkbeiner, S., Huang, E. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63113 · Cited by 315
Self-citationProgranulin, lysosomal regulation and neurodegenerative disease
Kao, A. W., McKay, A., Singh, P. P., Brunet, A., & Huang, E. J. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.36 · Cited by 258
Imaging and fluid biomarkers in frontotemporal dementia
Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210
Progranulin as a therapeutic target in neurodegenerative diseases
Rhinn, H., Tatton, N., McCaughey, S., Kurnellas, M., & Rosenthal, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.015 · Cited by 208
Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia
Dopper, E. G. P., Rombouts, S. A. R. B., Jiskoot, L. C., den Heijer, T., de Graaf, J. R. A., de Koning, I., Hammerschlag, A. R., Seelaar, H., Seeley, W. W., Veer, I. M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000583 · Cited by 152
Genetics of FTLD : overview and what else we can expect from genetic studies
Pottier, C., Ravenscroft, T. A., Sanchez‐Contreras, M., & Rademakers, R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13622 · Cited by 148
Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management
Seltman, R. E., & Matthews, B. R. (2012) · CNS Drugs · doi:10.2165/11640070-000000000-00000 · Cited by 132
Pottier, C., Zhou, X., Perkerson, R. B., Baker, M., Jenkins, G. D., Serie, D. J., Ghidoni, R., Benussi, L., Binetti, G., López de Munain, A., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30126-1 · Cited by 131
Self-citationTargeted manipulation of the sortilin–progranulin axis rescues progranulin haploinsufficiency
Lee, W. C., Almeida, S., Prudencio, M., Caulfield, T. R., Zhang, Y.-J., Tay, W. M., Bauer, P. O., Chew, J., Sasaguri, H., Jansen-West, K. R., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt534 · Cited by 125
Self-citationDevelopment of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Mossink, B., Negwer, M., Schubert, D., & Nadif Kasri, N. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03714-5 · Cited by 114
Prosaposin is a regulator of progranulin levels and oligomerization
Nicholson, A. M., Finch, N. A., Almeida, M., Perkerson, R. B., van Blitterswijk, M., Wojtas, A., Cenik, B., Rotondo, S., Inskeep, V., Almasy, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms11992 · Cited by 91
Self-citationProgranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers
Meeter, L. H. H., Patzke, H., Loewen, G., Dopper, E. G. P., Pijnenburg, Y. A. L., van Minkelen, R., & van Swieten, J. C. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000447738 · Cited by 87
Boxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Small molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration
Jiang, D., Li, T., Guo, C., Tang, T.-S., & Liu, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00953-4 · Cited by 54
Butler, V. J., Gao, F., Corrales, C. I., Cortopassi, W. A., Caballero, B., Vohra, M., Ashrafi, K., Cuervo, A. M., Jacobson, M. P., Coppola, G., et al. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008295 · Cited by 39
Self-citationSha, S. J., Miller, Z. A., Min, S., Zhou, Y., Brown, J., Mitic, L. L., Karydas, A., Koestler, M., Tsai, R., Corbetta‐Rastelli, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.002 · Cited by 36
“Thus, therapeutic approaches have focused on increasing PGRN levels, either by increasing transcription from the normal allele [4,5] or by modulating posttranslational mechanisms [6,7].”
BackgroundSelf-citationProgranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD
Feneberg, E., Steinacker, P., Volk, A. E., Weishaupt, J. H., Wollmer, M. A., Boxer, A., Tumani, H., Ludolph, A. C., & Otto, M. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-015-1486-1 · Cited by 36
“PGRN is an attractive target for therapeutics in FTLD, because low PGRN levels are associated with disease and the protein itself could be treated as a pharmacodynamic biomarker (Capell et al. 2011; Cenik et al. 2011).”
BackgroundLjubenkov, P. A., Edwards, L., Iaccarino, L., La Joie, R., Rojas, J. C., Koestler, M., Harris, B., Boeve, B. F., Borroni, B., van Swieten, J. C., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25584 · Cited by 30
Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression
Moreno-Yruela, C., Fass, D. M., Cheng, C., Herz, J., Olsen, C. A., & Haggarty, S. J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00281 · Cited by 27
Self-citationTelpoukhovskaia, M. A., Liu, K., Sayed, F. A., Etchegaray, J. I., Xie, M., Zhan, L., Li, Y., Zhou, Y., Le, D., Bahr, B. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70534-9 · Cited by 23
Precision Medicine for Frontotemporal Dementia
Liu, M.-N., Lau, C.-I., & Lin, C.-P. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00075 · Cited by 20
Metadata
- Authors
- Cenik, B., Sephton, C. F., Dewey, C. M., Xian, X., Wei, S., Yu, K., Niu, W., Coppola, G., Coughlin, S. E., Lee, S. E., Dries, D. R., Almeida, S., Geschwind, D. H., Gao, F.-B., Miller, B. L., Farese, R. V., Posner, B. A., Yu, G., & Herz, J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 286
- Issue
- 18
- Pages
- 16101-16108
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2015074014
- Cited by
- 147
- References
- 12
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.